SEC 13F Intelligence

Artal Group S.A. / ARWR

Artal Group S.A.’s Arrowhead Pharmaceuticals In Position

Does Artal Group S.A. own Arrowhead Pharmaceuticals In (ARWR)? Not currently — the last reported position was 3.19M shares worth $83M in Q2 2024; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$83M
Q2 2024
Shares
3.19M
% of Portfolio
+2.11%
Quarters Held
7
position exited

Position History ARWR

Reported value by quarter
Q1 ’20: $17MQ1 ’20Q1 ’23: $665Q1 ’23Q2 ’23: $194Q2 ’23Q3 ’23: $146Q3 ’23Q4 ’23: $31,465Q4 ’23Q1 ’24: $87MQ1 ’24Q2 ’24: $83MQ2 ’24filingsflow.com
QuarterSharesValue% of Portfolio
Q2 20243.19M$83M+2.11%
Q1 20243.04M$87M+2.21%
Q4 20231.03M$31,465+1.05%
Q3 20235.4K$146+0.01%
Q2 20235.4K$194+0.01%
Q1 202326.2K$665+0.04%
Q1 2020600.0K$17M+0.73%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Artal Group S.A.’s full portfolio or all institutional holders of ARWR.